Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice,Hepatology

当前位置： X-MOL 学术 › Hepatology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice
Hepatology ( IF 12.9 ) Pub Date : 2020-03-16 , DOI: 10.1002/hep.30975
Yunhuan Liu ₁ , Kefei Chen _{1,

2} , Fengyuan Li _{1,

3} , Zelin Gu ₁ , Qi Liu _{1,

4} , Liqing He ₅ , Tuo Shao ₁ , Qing Song _{1,

6} , Fenxia Zhu _{1,

7} , Lihua Zhang ₁ , Mengwei Jiang _{1,

3} , Yun Zhou ₁ , Shirish Barve _{1,

3,

8,

9} , Xiang Zhang _{3,

5,

8,

9} , Craig J McClain _{1,

3,

8,

9,

10} , Wenke Feng _{1,

3,

8,

9}

Affiliation

Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs). Modification of gut microbiota and repression of BA synthesis are potential strategies for the treatment of cholestatic liver disease. The purpose of this study was to examine the effects and to understand the mechanisms of the probiotic Lactobacillus rhamnosus GG (LGG) on hepatic BA synthesis, liver injury, and fibrosis in bile duct ligation (BDL) and multidrug resistance protein 2 knockout (Mdr2−/−) mice.

中文翻译：

益生菌LGG通过抑制小鼠肝脏胆汁酸合成和增强胆汁酸排泄来预防肝纤维化

胆汁淤积性肝病的特点是肠道菌群失调和过量的有毒肝胆汁酸（BA）。改变肠道微生物群和抑制 BA 合成是治疗胆汁淤积性肝病的潜在策略。本研究的目的是检查益生菌鼠李糖乳杆菌 GG (LGG) 对胆管结扎 (BDL) 和多药耐药蛋白 2 敲除 (Mdr2−) 中肝脏 BA 合成、肝损伤和纤维化的影响并了解其机制。 /−) 小鼠。

更新日期：2020-03-16

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11